Study on the Appropriate Timing of Postoperative Adaptive Radiotherapy for High-Grade Glioma

References

• Manon R, Hui S, Chinnaiyan P, et al. The impact of mid-treatment MRI on defining boost volumes in the radiation treatment of glioblastoma multiforme. Technol Cancer Res Treat. 2004;3(3):303–307. doi:10.1177/15330346040030030815161323
   PubMed Web of Science ®Google Scholar
• Tsien C, Gomez-Hassan D, Ten Haken RK, et al. Evaluating changes in tumor volume using magnetic resonance imaging during the course of radiotherapy treatment of high-grade gliomas: implications for conformal dose-escalation studies. Int J Radiat Oncol Biol Phys. 2005;62(2):328–332. doi:10.1016/j.ijrobp.2004.10.01015890571
   PubMed Web of Science ®Google Scholar
• Shukla D, Huilgol NG, Trivedi N, Mekala C. T2 weighted MRI in assessment of volume changes during radiotherapy of high grade gliomas. J Cancer Res Ther. 2005;1(4):235–238. doi:10.4103/0973-1482.1960117998661
   PubMedGoogle Scholar
• Kim TG, Lim DH. Interfractional variation of radiation target and adaptive radiotherapy for totally resected glioblastoma. J Korean Med Sci. 2013;28(8):1233–1237. doi:10.3346/jkms.2013.28.8.123323960453
   PubMed Web of Science ®Google Scholar
• Mehta S, Gajjar SR, Padgett KR, et al. Daily tracking of glioblastoma resection cavity, cerebral edema, and tumor volume with MRI-guided radiation therapy. Cureus. 2018;10(3):e2346.29796358
   PubMed Web of Science ®Google Scholar
• Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65(2):499–508. doi:10.1016/j.ijrobp.2005.12.00216517093
   PubMed Web of Science ®Google Scholar
• Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527–1535. doi:10.1056/NEJMoa06590117429084
   PubMed Web of Science ®Google Scholar
• Yan D, Ziaja E, Jaffray D, et al. The use of adaptive radiation therapy to reduce setup error: a Prospective Clinical Study. Int J Radiat Oncol Biol Phys. 1998;41(3):715–720. doi:10.1016/S0360-3016(97)00567-19635724
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhang Z, Wang X, et al. Intensity-modulated radiotherapy for gliomas: dosimetriceffects of changes in gross tumor volume on organs at risk and healthy brain tissue. Onco Targets Ther. 2016;9:3545–3554. doi:10.2147/OTT.S10045527366091
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-127157931
   PubMed Web of Science ®Google Scholar
• Cabrera AR, Kirkpatrick JP, Fiveash JB, et al. Radiation therapy for glioblastoma: executive summary of an American society for radiation oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2016;6(4):217–225. doi:10.1016/j.prro.2016.03.00727211230
   PubMed Web of Science ®Google Scholar
• Ali AN, Ogunleye T, Hardy CW, Shu HK, Curran WJ, Crocker IR. Improved hippocampal dose with reduced margin radiotherapy for glioblastoma multiforme. Radiat Oncol. 2014;9(1):20. doi:10.1186/1748-717X-9-2024411020
   PubMed Web of Science ®Google Scholar
• MacDonald SM, Ahmad S, Kachris S, et al. Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison. J Appl Clin Med Phys. 2007;8(2):47–60. doi:10.1120/jacmp.v8i2.242317592465
   PubMed Web of Science ®Google Scholar
• Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys. 1997;24(1):103–110. doi:10.1118/1.5980639029544
   PubMed Web of Science ®Google Scholar
• Lyman JT. Normal tissue complication probabilities: variable dose per fraction. Int J Radiat Oncol Biol Phys. 1992;22(2):247–250. doi:10.1016/0360-3016(92)90040-O1740391
   PubMed Web of Science ®Google Scholar
• Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys. 1989;16(6):1623–1630. doi:10.1016/0360-3016(89)90972-32722599
   PubMed Web of Science ®Google Scholar
• Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21(1):123–135. doi:10.1016/0360-3016(91)90172-Z2032883
   PubMed Web of Science ®Google Scholar
• Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg. 2000;93(Suppl 3):219–222. doi:10.3171/jns.2000.93.supplement_3.021911143252
   PubMed Web of Science ®Google Scholar
• Semenenko VA, Reitz B, Day E, Qi XS, Miften M, Li XA. Evaluation of a commercial biologically based IMRT treatment planning system. Med Phys. 2008;35(12):5851–5860. doi:10.1118/1.301355619175141
   PubMed Web of Science ®Google Scholar
• Shaw EG, Scheithauer BW, O’Fallon JR. Management of supratentorial low-grade gliomas. Oncology (Williston Park). 1993;7(7):97–104, 107. discussion 108–111. doi:10.1016/1053-4296(91)90006-s
   PubMedGoogle Scholar
• Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000;54(7):1442–1448. doi:10.1212/WNL.54.7.144210751254
   PubMed Web of Science ®Google Scholar
• Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20(8):2076–2084. doi:10.1200/JCO.2002.08.12111956268
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa04333015758009
   PubMed Web of Science ®Google Scholar
• Tsien CI, Brown D, Normolle D, et al. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. Clin Cancer Res. 2012;18(1):273–279. doi:10.1158/1078-0432.CCR-11-207322065084
   PubMed Web of Science ®Google Scholar
• Fink J, Born D, Chamberlain MC. Pseudoprogression: relevance with respect to treatment of high-grade gliomas. Curr Treat Options Oncol. 2011;12(3):240–252. doi:10.1007/s11864-011-0157-121594589
   PubMed Web of Science ®Google Scholar